Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Brain Tumor Drugs Market Outlook (2023 to 2033)

The brain tumor drugs market is estimated to record a 9.2% CAGR from 2023 to 2033. The market is likely to reach US$ 2.65 billion in 2023 and is expected to be worth US$ 6.30 billion in 2033.

Report Attribute Details
Brain Tumor Drugs Market Value (2023) US$ 2.65 billion
Brain Tumor Drugs Market Anticipated Value (2033) US$ 6.30 billion
Brain Tumor Drugs Market Growth Rate (2023 to 2033) 9.2% CAGR

Surging Neurological Condition to Increase the Demand

Rising awareness of neurological illnesses in children and adults is boosting the brain tumor drugs market. Brain illnesses, which include several neurodegenerative, psychiatric, and developmental problems, are the reasons for death associated with brain damage worldwide. According to the American Medical Association (AMA), more than 20% of the world's population is expected to be 65 years or older by 2050.

Cancer, a global public health issue, ranks second in the cause of morbidity in the United States. The global elderly population and the emergence of novel diseases are expected to drive growth in the brain tumor medication market.

The brain tumor medication tackles abnormal cell growth in the brain and is administered in combination or alone, depending on their location, shape, and size. For example, Temozolomide, Avastin, and BiCNU carmustine are medications used to treat brain tumors. Government initiatives and increased knowledge about medical breakthroughs are expected to propel the industry growth in the coming years.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2017 to 2022 Brain Tumor Drugs Market Outlook in Comparison to 2023 to 2033 Growth Forecast

The brain tumor drugs market was worth US$ 2.52 billion in 2022, at a 9% CAGR from 2017 to 2022.

Developments in medical treatment and advanced patient care for brain illnesses are available globally. Experiments and advancements in combination therapy with current and novel medications have resulted in people suffering from brain tumor problems.

The increased use of targeted therapeutics may restrain market growth. The pharmaceutical industry is focused on developing drugs that specifically target the eradication of cancer cells while causing no harm to normal bodily cells, as some cancer spread to the brain through different body parts. Bevacizumab, for example, prevents cancer cell replication, allowing cytotoxic chemotherapy medications that limit normal cell division to be used. Furthermore, the growing acceptability of these procedures and therapies is anticipated to create roadblocks in the use of traditional brain tumor medications, threatening market expansion.

Historical CAGR (2017 to 2022) 9%
Forecast CAGR (2023 to 2033) 9.2%
  • Short Term (2023 to 2026): The increasing prevalence of neurological disorders worldwide is the primary driving factor responsible for the growth of the brain tumor market.
  • Medium Term (2026 to 2029): Prolonged life expectancy, increased virus exposure, and sedentary lifestyle, neurological illnesses have been highlighted as one of the most prevalent disorders.
  • Long Term (2029 to 2033): Researchers are working on new techniques to diagnose a brain tumor, such as biomarker tests that can estimate a patient’s prognosis.

As per the FMI analysts, a valuation of US$ 6.30 billion by 2033 is estimated for the market.

Year Market Value
2016 US$ 1.43 billion
2021 US$ 2.23 billion
2022 US$ 2.52 billion
2023 US$ 2.65 billion
2033 US$ 6.30 billion

Comparative Analysis of Adjacent Markets

Brain Tumor Drugs Market:

Differentiating Aspects Brain Tumor Drugs Market
Anticipated CAGR (2023 to 2033) 9.2%
Market Valuation (2023) US$ 2.65 billion
Growth Factors Rising cases of brain cancer
Future Opportunities A robust drug pipeline is in demand
Market Trends Immunotherapy is expected to experience rapid growth

Brain Tumor Treatment Market:

Differentiating Aspects Brain Tumor Treatment Market
Anticipated CAGR (2023 to 2033) 7.4%
Market Valuation (2023) US$ 3,164.19 billion
Growth Factors Rising incidence of brain tumors has increased the necessity for effective therapy
Future Opportunities Increased pharmaceutical R&D spending is likely to fuel the worldwide brain tumor therapy market
Market Trends Due to enormous technological breakthroughs in the healthcare industry, innovative therapies for brain conditions are producing effective outcomes.

Brain Cancer Therapeutics Market:

Differentiating Aspects Brain Cancer Therapeutics Market
Anticipated CAGR (2023 to 2033) 10%
Market Valuation (2023) US$ 3,072.19 billion
Growth Factors Brain and CNS cancer-related death to fuel the brain cancer therapeutics market, globally
Future Opportunities Increasing research and development spending to create new treatment approaches and medical equipment
Market Trends Increased research into new treatments and radiation therapy
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Increased Incidence of Brain Cancer Cases to Drive Market Growth

Factors such as changing lifestyles and eating choices increased urbanization, and smoking habit is surging the cases of brain conditions among adults and elderly people. According to the WHO, nearly 23.0% of adults used tobacco in 2020. As a result, the increased incidence of smoking among adults contributes to the global increase in cancer cases.Furthermore, as the prevalence of various cancer kinds rises, so does the rate of diagnosis and treatment. For example, according to GLOBOCAN, roughly 19,300,000 persons worldwide were diagnosed with cancer in 2020.

Brain tumors account for around 1% to 2% of cancer death in the United States, with a significant fatality rate. The increased occurrence of brain tumors is due to factors such as strong radiation exposure that causes DNA to change and eventually lead to cancer.

Research and Development Pipeline for Novel Treatments

The rising prevalence of brain cancer and rising diagnosis rates, particularly in industrialized nations, are creating a pool of patients in need of treatment. This, together with market participants' increased focus on research and development activities to introduce new medications with clinical benefits for the treatment and management of the illness, is propelling the brain tumor pharmaceuticals market forward.

Unmet needs, such as the availability of these medications on the market, associated with the various stages of brain cancer management, may aid in shifting research and development priorities and improving physicians' therapeutic approaches. As a result, many pharmaceutical companies are investing in research and development to find novel medications for the treatment of brain tumors.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

High Treatment Costs along with Limited Reimbursement, are expected to Slow Market Growth

Several side effects associated with brain tumor treatments, as well as the high costs of these drugs, are a few reasons restricting market expansion. Furthermore, lower brain tumor diagnosis and treatment rates, as well as limited reimbursement for these medications in underdeveloped countries, are projected to restrain market growth.

Brain cancer diagnosis and treatment rates are substantially lower in emerging countries than in developed countries. In China, for example, the prevalence of brain tumors was 14.82 per 100,000 individuals in 2021.

Advancement in Brain Tumor Diagnosis to Support Market Growth

Early detection and treatment of brain tumors are difficult due to variables such as the body's blood-brain barrier, which normally protects the spinal cord and brain from harmful substances. This barrier, however, also keeps many forms of chemotherapy out. Thus, improved methods for brain tumor diagnosis and treatment are required. The prevalence of brain tumors is steadily growing, which can be ascribed to advancements in detection and treatment procedures.

Prognostic indicators are vital in the creation of tailored medications and in increasing the survival rate of persons with brain tumors. Neurological and neuroimaging studies are utilized to diagnose glioma at an advanced stage. Assessment of genetic characteristics in biopsy specimens of brain tumor patients is one of the important tools for improved diagnosis and treatment of brain tumors. Furthermore, circulating nucleic acid in the blood and other biological fluids can be employed as a marker for the early detection and treatment of brain tumors.

Success Rates of Immunotherapy May Drive Market Growth

Immunotherapy is a cancer treatment that aids the immune system in its battle against cancer. Immunotherapies are employed in a range of cancer treatments. Immunotherapy holds promise for treating brain cancer, which has traditionally been treated with chemotherapy, radiation therapy, and surgery. Immunotherapy, often known as biological treatment, uses living organisms to treat disease.

Vaccines are a promising new type of immunotherapy that boosts the immune system's ability to fight cancer. This market's growth is expected to be fueled by novel immunotherapy treatments for brain cancer. Furthermore, there are numerous authorized immunotherapies for various brain malignancies, and industry companies and universities are heavily working on researching and marketing new brain tumor immunotherapies.

As a result, this market may grow as universities increase their efforts to develop novel immunotherapy treatments. As a result, the aforementioned factors have contributed to the market's overall expansion.

Market is likely to be Dominated by North America

The North American brain tumor market is expected to grow significantly during the forecast period. The United States is expected to lead the market because of its developed healthcare industry and increased awareness of sophisticated technologies among the populace in this area.

According to the American Brain Tumor Association, about 84,000 people were diagnosed with a primary brain tumor in 2021, and roughly 18,000 died as a result of a primary malignant brain tumor. Furthermore, more than 28,000 youngsters in the United States were diagnosed with a brain tumor in 2021, according to the same source.

The increased occurrence of brain tumors is likely to boost regional growth. Furthermore, the market analyzed in the United States is projected to be driven by regular product releases and pharmacological approvals, as well as considerable R&D initiatives for the treatment of brain tumors.

The surging clinical trials for brain tumor therapy in the United States are likely to boost the expansion of this market. As a result of the foregoing factors, the North American brain tumor drugs market is expected to expand significantly over the forecast period.

The market in Latin America is expanding due to an increase in brain tumor diagnosis and treatment, which has created a demand for these medications in the region. This, combined with the introduction of new pharmaceuticals in the region, is contributing to the region's market growth.

Common CNS Cancer in Europe Boosts the Market

The frequency of primary brain tumors, favorable regulatory circumstances in leading European nations, and an increased emphasis on research activities for producing brain tumor drugs are driving the market in Europe.

According to national and regional estimates, around US$ 115.00 billion was spent on cancer care in Europe in 2019, with direct expenditures on cancer medications accounting for nearly US$ 35.00 to US$ 40.00 billion.

Market in Asia Pacific is expected to Accelerate due to Rising Awareness

The market in the Asia Pacific is influenced by rising awareness of brain cancer, early detection, and increased clinical trial in drug delivery for brain cancer cells. Furthermore, increased knowledge regarding brain tumors and their forms in the region boosts the market growth.

According to brain tumor research, the average rating of brain tumor care in Australia was the lowest of all cancers, with a score of 8.37 out of 10. Moreover, in 2018, nearly two thousand people died due to brain cancer in the Asia Pacific.

Competitive Landscape

Prominent Participants in the Market

  • AstraZeneca plc
  • Johnson & Johnson Inc
  • Merck & Co
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • Y-mAbs Therapeutics, Inc
  • Shimadzu Corporation
  • Bristol-Myers Squibb
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd
  • Among others

Scope of Report

Attribute Details
Market Size Value in 2023 US$ 2.65 billion
Market Size Value in 2033 US$ 6.30 billion
Market Analysis US$ billion for Value
Key Region Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • The Middle East and Africa
Key Segments
  • By Therapy
  • By Indication
  • By Distribution Channel
  • By Region
Key Companies Profiled
  • AstraZeneca plc
  • Johnson & Johnson Inc
  • Merck & Co
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • Y-mAbs Therapeutics, Inc
  • Shimadzu Corporation
  • Bristol-Myers Squibb
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd
  • Among others
Report Coverage Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing Available upon Request

Key Segment

By Therapy:

  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Others

By Indication:

  • Pituitary
  • Meningioma
  • Glioma
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail & Online Pharmacy

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • The Middle East and Africa

Frequently Asked Questions

What is the Key Driver of the Brain Tumor Drugs Market?

Surging neurological condition is the key driver of the market.

Which Factor is Restraining the Market Growth?

The increased use of targeted therapeutics may restrain the market growth.

What will be the Growth Rate until 2033?

The market is likely to experience a 9.2% CAGR until 2033.

What is the Estimated Market Value in 2033?

The market is predicted to be worth US$ 6.30 billion in 2033.

Which Region will Dominate the Market?

North America is likely to dominate the market.

Table of Content

1. Executive Summary | Brain Tumor Drugs Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Temozolomide

        5.3.2. Carmustine

        5.3.3. Cisplatin

        5.3.4. Bevacizumab

        5.3.5. Geftinib

        5.3.6. Erlotinib

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033

        6.3.1. Targeted Therapy

        6.3.2. Chemotherapy

        6.3.3. Immunotherapy

    6.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Indication , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication , 2023 to 2033

        7.3.1. Pituitary Tumor

        7.3.2. Meningioma

        7.3.3. Glioblastoma

    7.4. Y-o-Y Growth Trend Analysis By Indication , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Indication , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. South Asia

        9.3.5. East Asia

        9.3.6. Oceania

        9.3.7. MEA

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. USA

            10.2.1.2. Canada

        10.2.2. By Drug Class

        10.2.3. By Therapy

        10.2.4. By Indication

        10.2.5. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Therapy

        10.3.4. By Indication

        10.3.5. By Distribution Channel

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Drug Class

        11.2.3. By Therapy

        11.2.4. By Indication

        11.2.5. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Therapy

        11.3.4. By Indication

        11.3.5. By Distribution Channel

    11.4. Key Takeaways

12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. United kingdom

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Drug Class

        12.2.3. By Therapy

        12.2.4. By Indication

        12.2.5. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Therapy

        12.3.4. By Indication

        12.3.5. By Distribution Channel

    12.4. Key Takeaways

13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Rest of South Asia

        13.2.2. By Drug Class

        13.2.3. By Therapy

        13.2.4. By Indication

        13.2.5. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Therapy

        13.3.4. By Indication

        13.3.5. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Drug Class

        14.2.3. By Therapy

        14.2.4. By Indication

        14.2.5. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Therapy

        14.3.4. By Indication

        14.3.5. By Distribution Channel

    14.4. Key Takeaways

15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. Australia

            15.2.1.2. New Zealand

        15.2.2. By Drug Class

        15.2.3. By Therapy

        15.2.4. By Indication

        15.2.5. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class

        15.3.3. By Therapy

        15.3.4. By Indication

        15.3.5. By Distribution Channel

    15.4. Key Takeaways

16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Drug Class

        16.2.3. By Therapy

        16.2.4. By Indication

        16.2.5. By Distribution Channel

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Drug Class

        16.3.3. By Therapy

        16.3.4. By Indication

        16.3.5. By Distribution Channel

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Drug Class

            17.1.2.2. By Therapy

            17.1.2.3. By Indication

            17.1.2.4. By Distribution Channel

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Drug Class

            17.2.2.2. By Therapy

            17.2.2.3. By Indication

            17.2.2.4. By Distribution Channel

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Drug Class

            17.3.2.2. By Therapy

            17.3.2.3. By Indication

            17.3.2.4. By Distribution Channel

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Drug Class

            17.4.2.2. By Therapy

            17.4.2.3. By Indication

            17.4.2.4. By Distribution Channel

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Drug Class

            17.5.2.2. By Therapy

            17.5.2.3. By Indication

            17.5.2.4. By Distribution Channel

    17.6. United kingdom

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Drug Class

            17.6.2.2. By Therapy

            17.6.2.3. By Indication

            17.6.2.4. By Distribution Channel

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Drug Class

            17.7.2.2. By Therapy

            17.7.2.3. By Indication

            17.7.2.4. By Distribution Channel

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Drug Class

            17.8.2.2. By Therapy

            17.8.2.3. By Indication

            17.8.2.4. By Distribution Channel

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Drug Class

            17.9.2.2. By Therapy

            17.9.2.3. By Indication

            17.9.2.4. By Distribution Channel

    17.10. India

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Drug Class

            17.10.2.2. By Therapy

            17.10.2.3. By Indication

            17.10.2.4. By Distribution Channel

    17.11. Malaysia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Drug Class

            17.11.2.2. By Therapy

            17.11.2.3. By Indication

            17.11.2.4. By Distribution Channel

    17.12. Singapore

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Drug Class

            17.12.2.2. By Therapy

            17.12.2.3. By Indication

            17.12.2.4. By Distribution Channel

    17.13. Thailand

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Drug Class

            17.13.2.2. By Therapy

            17.13.2.3. By Indication

            17.13.2.4. By Distribution Channel

    17.14. China

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Drug Class

            17.14.2.2. By Therapy

            17.14.2.3. By Indication

            17.14.2.4. By Distribution Channel

    17.15. Japan

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Drug Class

            17.15.2.2. By Therapy

            17.15.2.3. By Indication

            17.15.2.4. By Distribution Channel

    17.16. South Korea

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Drug Class

            17.16.2.2. By Therapy

            17.16.2.3. By Indication

            17.16.2.4. By Distribution Channel

    17.17. Australia

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Drug Class

            17.17.2.2. By Therapy

            17.17.2.3. By Indication

            17.17.2.4. By Distribution Channel

    17.18. New Zealand

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Drug Class

            17.18.2.2. By Therapy

            17.18.2.3. By Indication

            17.18.2.4. By Distribution Channel

    17.19. GCC Countries

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Drug Class

            17.19.2.2. By Therapy

            17.19.2.3. By Indication

            17.19.2.4. By Distribution Channel

    17.20. South Africa

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Drug Class

            17.20.2.2. By Therapy

            17.20.2.3. By Indication

            17.20.2.4. By Distribution Channel

    17.21. Israel

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Drug Class

            17.21.2.2. By Therapy

            17.21.2.3. By Indication

            17.21.2.4. By Distribution Channel

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Drug Class

        18.3.3. By Therapy

        18.3.4. By Indication

        18.3.5. By Distribution Channel

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Genetech USAA

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Bristol Myers Squibb

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Hoffmann- La Roche

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. AstraZeneca Plc.

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Pfizer Inc.

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. Novartis AG

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. Antisense Pharma

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. Merck & Co

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. MacLeod’s Pharmaceutical Limited

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Mankind Pharma

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

        19.1.11. Siemens Healthineers AG

            19.1.11.1. Overview

            19.1.11.2. Product Portfolio

            19.1.11.3. Profitability by Market Segments

            19.1.11.4. Sales Footprint

            19.1.11.5. Strategy Overview

                19.1.11.5.1. Marketing Strategy

        19.1.12. Dr. Reddy’s Laboratories Ltd.

            19.1.12.1. Overview

            19.1.12.2. Product Portfolio

            19.1.12.3. Profitability by Market Segments

            19.1.12.4. Sales Footprint

            19.1.12.5. Strategy Overview

                19.1.12.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Indication , 2018 to 2033

Table 5: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 9: North America Market Value (US$ Million) Forecast by Indication , 2018 to 2033

Table 10: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 13: Latin America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 14: Latin America Market Value (US$ Million) Forecast by Indication , 2018 to 2033

Table 15: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 18: Europe Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 19: Europe Market Value (US$ Million) Forecast by Indication , 2018 to 2033

Table 20: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 21: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 23: South Asia Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 24: South Asia Market Value (US$ Million) Forecast by Indication , 2018 to 2033

Table 25: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 26: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 27: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 28: East Asia Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 29: East Asia Market Value (US$ Million) Forecast by Indication , 2018 to 2033

Table 30: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 31: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 32: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 33: Oceania Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 34: Oceania Market Value (US$ Million) Forecast by Indication , 2018 to 2033

Table 35: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 36: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 37: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 38: MEA Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 39: MEA Market Value (US$ Million) Forecast by Indication , 2018 to 2033

Table 40: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Indication , 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 9: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 12: Global Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 13: Global Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 14: Global Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 15: Global Market Value (US$ Million) Analysis by Indication , 2018 to 2033

Figure 16: Global Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033

Figure 17: Global Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033

Figure 18: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 21: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 22: Global Market Attractiveness by Therapy, 2023 to 2033

Figure 23: Global Market Attractiveness by Indication , 2023 to 2033

Figure 24: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 25: Global Market Attractiveness by Region, 2023 to 2033

Figure 26: North America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 27: North America Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 28: North America Market Value (US$ Million) by Indication , 2023 to 2033

Figure 29: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 37: North America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 38: North America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 39: North America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 40: North America Market Value (US$ Million) Analysis by Indication , 2018 to 2033

Figure 41: North America Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033

Figure 42: North America Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033

Figure 43: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 46: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 47: North America Market Attractiveness by Therapy, 2023 to 2033

Figure 48: North America Market Attractiveness by Indication , 2023 to 2033

Figure 49: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 50: North America Market Attractiveness by Country, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 52: Latin America Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 53: Latin America Market Value (US$ Million) by Indication , 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 59: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 62: Latin America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 63: Latin America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 65: Latin America Market Value (US$ Million) Analysis by Indication , 2018 to 2033

Figure 66: Latin America Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033

Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033

Figure 68: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 71: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 72: Latin America Market Attractiveness by Therapy, 2023 to 2033

Figure 73: Latin America Market Attractiveness by Indication , 2023 to 2033

Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 76: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 77: Europe Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 78: Europe Market Value (US$ Million) by Indication , 2023 to 2033

Figure 79: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 80: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 84: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 85: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 86: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 87: Europe Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 88: Europe Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 89: Europe Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 90: Europe Market Value (US$ Million) Analysis by Indication , 2018 to 2033

Figure 91: Europe Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033

Figure 92: Europe Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033

Figure 93: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 96: Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 97: Europe Market Attractiveness by Therapy, 2023 to 2033

Figure 98: Europe Market Attractiveness by Indication , 2023 to 2033

Figure 99: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 100: Europe Market Attractiveness by Country, 2023 to 2033

Figure 101: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 102: South Asia Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 103: South Asia Market Value (US$ Million) by Indication , 2023 to 2033

Figure 104: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 105: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 106: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 109: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 110: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 112: South Asia Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 113: South Asia Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 115: South Asia Market Value (US$ Million) Analysis by Indication , 2018 to 2033

Figure 116: South Asia Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033

Figure 117: South Asia Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033

Figure 118: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 119: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 120: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 121: South Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 122: South Asia Market Attractiveness by Therapy, 2023 to 2033

Figure 123: South Asia Market Attractiveness by Indication , 2023 to 2033

Figure 124: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 125: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 126: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 127: East Asia Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 128: East Asia Market Value (US$ Million) by Indication , 2023 to 2033

Figure 129: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 130: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 131: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 134: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 135: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 137: East Asia Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 138: East Asia Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 140: East Asia Market Value (US$ Million) Analysis by Indication , 2018 to 2033

Figure 141: East Asia Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033

Figure 142: East Asia Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033

Figure 143: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 144: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 145: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 146: East Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 147: East Asia Market Attractiveness by Therapy, 2023 to 2033

Figure 148: East Asia Market Attractiveness by Indication , 2023 to 2033

Figure 149: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 150: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 151: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 152: Oceania Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 153: Oceania Market Value (US$ Million) by Indication , 2023 to 2033

Figure 154: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 155: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 156: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 159: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 160: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 162: Oceania Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 163: Oceania Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 165: Oceania Market Value (US$ Million) Analysis by Indication , 2018 to 2033

Figure 166: Oceania Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033

Figure 167: Oceania Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033

Figure 168: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 169: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 170: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 171: Oceania Market Attractiveness by Drug Class, 2023 to 2033

Figure 172: Oceania Market Attractiveness by Therapy, 2023 to 2033

Figure 173: Oceania Market Attractiveness by Indication , 2023 to 2033

Figure 174: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 175: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 176: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 177: MEA Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 178: MEA Market Value (US$ Million) by Indication , 2023 to 2033

Figure 179: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 180: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 181: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 184: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 185: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 186: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 187: MEA Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 188: MEA Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 189: MEA Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 190: MEA Market Value (US$ Million) Analysis by Indication , 2018 to 2033

Figure 191: MEA Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033

Figure 192: MEA Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033

Figure 193: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 194: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 195: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 196: MEA Market Attractiveness by Drug Class, 2023 to 2033

Figure 197: MEA Market Attractiveness by Therapy, 2023 to 2033

Figure 198: MEA Market Attractiveness by Indication , 2023 to 2033

Figure 199: MEA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 200: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Brain Tumor Treatment Market

Published : July 2023

Explore Healthcare Insights

View Reports